المؤلفون: Bruggen JACV; 2Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, Netherlands., Peters FS; Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, Netherlands., Mes MJ; Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, The Netherlands, Amsterdam, Netherlands., Rietveld JM; Amsterdam Infection & Immunity Institute, Amsterdam UMC, Amsterdam, Amsterdam, Netherlands., Cerretani E; Department of Hematology, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam, The Netherlands, Amsterdam, Netherlands., Cretenet G; Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, Netherlands., van Kampen RJW; Zuyerland Medical Center, Sittard-Geleen, Netherlands., Jongejan A; Amsterdam University Medical Centers, Location AMC, Amsterdam, Netherlands., Moerland PDD; Amsterdam UMC, Amsterdam, Netherlands., Melenhorst JJ; Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio, United States., Eldering E; Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, Netherlands., Kater AP; Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, Netherlands.

المصدر: Blood advances [Blood Adv] 2024 Jul 23. Date of Electronic Publication: 2024 Jul 23.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

المؤلفون: Waanders L; Department of Medical Microbiology and Infection Control, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands.; Amsterdam institute for Infection and Immunity, Infectious Diseases, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, Netherlands., van der Donk LEH; Amsterdam institute for Infection and Immunity, Infectious Diseases, Amsterdam, Netherlands.; Department of Experimental Immunology, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands., Ates LS; Department of Experimental Immunology, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands., Maaskant J; Department of Medical Microbiology and Infection Control, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands., van Hamme JL; Amsterdam institute for Infection and Immunity, Infectious Diseases, Amsterdam, Netherlands.; Department of Experimental Immunology, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands., Eldering E; Amsterdam institute for Infection and Immunity, Infectious Diseases, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, Netherlands.; Department of Experimental Immunology, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands.; Amsterdam institute for Infection and Immunity, Cancer Immunology, Amsterdam, Netherlands.; The Lymphoma and Myeloma Center Amsterdam, LYMMCARE, Amsterdam, Netherlands., van Bruggen JAC; Amsterdam institute for Infection and Immunity, Infectious Diseases, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, Netherlands.; Department of Experimental Immunology, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands.; Amsterdam institute for Infection and Immunity, Cancer Immunology, Amsterdam, Netherlands., Rietveld JM; Amsterdam institute for Infection and Immunity, Infectious Diseases, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, Netherlands.; Department of Experimental Immunology, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands.; Amsterdam institute for Infection and Immunity, Cancer Immunology, Amsterdam, Netherlands., Bitter W; Department of Medical Microbiology and Infection Control, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands.; Amsterdam institute for Infection and Immunity, Infectious Diseases, Amsterdam, Netherlands.; Amsterdam institute for Life and Environment, Vrije Universiteit, Amsterdam, Netherlands., Geijtenbeek TBH; Amsterdam institute for Infection and Immunity, Infectious Diseases, Amsterdam, Netherlands c.kuijl@amsterdamumc.nl t.b.geijtenbeek@amsterdamumc.nl.; Department of Experimental Immunology, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands., Kuijl CP; Department of Medical Microbiology and Infection Control, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands c.kuijl@amsterdamumc.nl t.b.geijtenbeek@amsterdamumc.nl.; Amsterdam institute for Infection and Immunity, Infectious Diseases, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, Netherlands.

المصدر: Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Apr; Vol. 11 (4).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Interferon Type I* , Neoplasms*/metabolism, Humans ; Salmonella typhimurium/metabolism ; Ectopic Gene Expression ; Nucleotidyltransferases/genetics ; Nucleotidyltransferases/metabolism ; Macrophages/metabolism ; Dendritic Cells/metabolism ; Tumor Microenvironment

المؤلفون: Martens AWJ; Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Amsterdam, the Netherlands.; Amsterdam Infection & Immunity Institute, Amsterdam, the Netherlands., Rietveld JM; Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., de Boer R; Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Peters FS; Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Amsterdam, the Netherlands.; Amsterdam Infection & Immunity Institute, Amsterdam, the Netherlands., Ngo A; Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., van Mil LWHG; Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., de Heer K; Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Department of Hematology, Flevoziekenhuis, Almere, the Netherlands., Spaargaren M; Cancer Center Amsterdam, Amsterdam, the Netherlands.; Department of Pathology, University of Amsterdam, the Netherlands.; Lymphoma and Myeloma Center Amsterdam, LYMMCARE, the Netherlands., Verkleij CPM; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., van de Donk NWCJ; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Adams HC 3rd; Janssen Pharmaceutical Companies of Johnson & Johnson, Philadelphia, Pennsylvania., Eldering E; Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Amsterdam, the Netherlands.; Amsterdam Infection & Immunity Institute, Amsterdam, the Netherlands.; Lymphoma and Myeloma Center Amsterdam, LYMMCARE, the Netherlands., van Noesel CJM; Department of Pathology, University of Amsterdam, the Netherlands.; Lymphoma and Myeloma Center Amsterdam, LYMMCARE, the Netherlands., Verona R; Janssen Pharmaceutical Companies of Johnson & Johnson, Philadelphia, Pennsylvania., Kater AP; Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Amsterdam, the Netherlands.; Amsterdam Infection & Immunity Institute, Amsterdam, the Netherlands.; Lymphoma and Myeloma Center Amsterdam, LYMMCARE, the Netherlands.

المصدر: Cancer research communications [Cancer Res Commun] 2022 May 09; Vol. 2 (5), pp. 330-341. Date of Electronic Publication: 2022 May 09 (Print Publication: 2022).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: eCollection Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun

مواضيع طبية MeSH: Antibodies, Bispecific*/pharmacology , Antibodies, Bispecific*/therapeutic use , Antineoplastic Agents* , Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy , Lymphoma, B-Cell*/drug therapy , Multiple Myeloma*, Humans ; Amyloid Precursor Protein Secretases ; B-Cell Maturation Antigen ; T-Lymphocytes